Zachary Bessette

GU Oncology Now

After approximately 4 years of follow-up data, enfortumab vedotin (EV) plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC).New data from the <a href="https://meetinglibrary.asco.org/embargo/record/218065/abstract" target="_blank" rel="noopener">EV-103 dose escalation/cohort A</a> are presented at the American Society of Clinical Oncology 2023 Annual Meeting.EV plus pembrolizumab has shown a manageable safety profile and promising antitumor activity in EV-103 dose escalation/cohort A and cohort K.Shilpa Gupta, MD, and colleagues reported updated safety, efficacy, and survival data, as well as subsequent therapies for dose escalation/cohort A after nearly 4 years of follow-up. Patients initially received 3-week cycles of EV (1.25 mg/kg on days 1 and 8) in combination with pembrolizumab (day 1).The primary end point was safety and tolerability, while secondary end points included confirmed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).As of September 2022, Dr. Gupta and colleagues reported that 45 patients with first-line cisplatin-ineligible la/mUC received treatment. All patients discontinued treatment and 18 patients remain on the study. After a median follow-up of 47 months, the confirmed ORR after a median of 9 cycles was 73% (95% CI, 58.1-85.4). Median PFS was 12.7 months (95% CI, 6.11 to not reached) with a 12-month PFS of 55.0% (95% CI, 38.84-68.85). Median OS was 26.1 months (95% CI, 15.51 to not reached) with a 12-month OS of 83.4% (95% CI, 68.25-91.72).The most commonly reported treatment-related adverse events (trAEs) for EV were skin reactions (66.7%), peripheral neuropathy (62.2%), and ocular disorders (40.0%), while the most common trAEs of special interest for pembrolizumab were severe skin reactions (24.4%), pneumonitis (8.9%), colitis (6.7%), and hypothyroidism (6.7%).Additionally, researchers shared that 60% of patients received subsequent cancer-related therapies, including systemic therapy (48.9%), surgery (8.9%), and palliative radiotherapy (8.9%). The most common second-line therapies were pembrolizumab (17.8%), carboplatin-based therapy (11.1%), and EV (6.7%).&ldquo;These results are concordant with previously reported dose escalation/cohort A data by investigator assessment and support the evaluation of EV plus pembrolizumab in ongoing phase 3 studies in UC,&rdquo; study authors concluded.

EV-103 Cohort A: Long-term Outcomes of EV Plus Pembrolizumab in First-line mUC

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

After 4 years of follow-up data, EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.

EV-103 Cohort A: Long-term Outcomes of EV Plus Pembrolizumab

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe